---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-062109"
form_type: "8-K"
ticker: "FDMT"
cik: "0001650648"
company_name: "4D Molecular Therapeutics, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:51:40.646646+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# 4DMT Q3 2023 net loss narrows to $10.3M; cash $320M, runway into H1 2026; clinical progress across pipeline

## Summary
- Net loss of $10.3M versus $25.7M in Q3 2022; decrease primarily due to $20M upfront from Astellas License Agreement.
- Cash, cash equivalents and marketable securities $320M as of Sep 30, 2023, up from $218M at Dec 31, 2022; runway into first half of 2026.
- Completed enrollment of 4D-150 PRISM Phase 2 Dose Expansion for wet AMD nearly two quarters ahead of schedule; interim data expected early 2024.
- Received EMA PRIME designation for 4D-150; reached agreement with FDA on plan to lift clinical hold on 4D-310 for Fabry disease cardiomyopathy.
- R&D expenses rose to $25.1M from $18.9M driven by clinical trial progression and higher headcount; G&A expenses $9.1M versus $8.1M.

## SEC filing metadata
- accession: 0000950170-23-062109
- form_type: 8-K
- ticker: FDMT
- cik: 0001650648
- company_name: 4D Molecular Therapeutics, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650648/000095017023062109/0000950170-23-062109-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650648/000095017023062109/fdmt-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-062109
- JSON: https://secwatch.observer/filing/0000950170-23-062109.json
- Plain text: https://secwatch.observer/filing/0000950170-23-062109.txt

## Key facts
- Earnings Releases
  4D Molecular Therapeutics, Inc. reported financial results for the three months ended September 30, 2023.
  - Period: the three months ended September 30, 2023
  - Result: reported results
  source text: On November 9, 2023, 4D Molecular Therapeutics, Inc. (“4DMT”) announced its financial results for the three months ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1650648/000095017023062109/0000950170-23-062109-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.